Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17102156 | 0.90 | HTR6 (0.37) | HTR6 | |
| SCHEMBL17097049 | 0.90 | HTR6 (0.45) | HTR6TGFBR1GPR119MMP13 | |
| SCHEMBL17097179 | 0.88 | HTR6 (0.40) | HTR6 | |
| SCHEMBL17097157 | 0.86 | HTT (0.40) | HTR6GPR119TDO2 | |
| SCHEMBL17120433 | 0.86 | HTR6 (0.38) | HTR6BCHE | |
| SCHEMBL17097222 | 0.84 | HTR6 (0.46) | HTR6 | |
| SCHEMBL17097264 | 0.84 | HTR6 (0.45) | HTR6TGFBR1GPR119BCHERORC | |
| SCHEMBL17097195 | 0.83 | GRM2 (0.41) | HTR6 | |
| SCHEMBL17097232 | 0.82 | HTR6 (0.45) | HTR6TGFBR1GPR119BCHERORC | |
| SCHEMBL17096912 | 0.82 | HTR6 (0.38) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015140717-A9 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-03-24 | — | — | WO | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 47/4885TGFBR1 4368/4885GPR119 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.